Novartis shares plunge after three clinical trial failures in a week

Novartis shares fell roughly 10-12% in premarket trading after three consecutive clinical trial failures within a week, wiping out about $20 billion in market value and putting the stock on track for its worst daily performance since March 2020. The biggest setback came from its treatment del desiran.

Detected & updated continuously · Source: Nebula